2026-10-19T00:23:41Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/120592026-10-18T21:13:25Zopenairedrivercom_ebyu_10000col_ebyu_10001

Bromelain protects against cisplatin-induced ocular toxicity through mitigating oxidative stress and inflammationFerah Okkay, IrmakOkkay, UfukBayram, CemilCicek, BetulSezen, SelmaAydin, Ismail CagriMendil, Ali SefaHacimuftuoglu, AhmetBromelaincisplatininflammationocular toxicityoxidative stressratAntioxidantsBromelainsHumansNF-kappa BToxic Optic NeuropathyTumor Necrosis Factor-alpha8 hydroxydeoxyguanosinecaspase 3immunoglobulin enhancer binding proteininterleukin 10interleukin 1betamalonaldehydemessenger RNAreactive oxygen metabolitesuperoxide dismutasetumor necrosis factorantioxidantanimal experimentanimal modelanimal tissueantiinflammatory activityArticlebiochemical analysiscontrolled studyThe aim of this study was to investigate the molecular, biochemical, and histopathological effects of bromelain, which has antioxidant and anti-inflammatory properties, against cisplatin-induced ocular toxicity. The groups were designed as (1) Control, (2) Cisplatin (7 mg/kg, intraperitoneally), (3) Cisplatin + Bromelain (50 mg/kg, orally for 14 consecutive days), (4) Cisplatin + Bromelain (100 mg/kg, orally for 14 consecutive days). The activity of total antioxidant capacity (TAC) and total oxidant status (TOS) and levels of reactive oxygen species (ROS), superoxide dismutase (SOD), malondialdehyde (MDA), interleukin-1β (IL-1β), IL-10, nuclear factor kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α) and 8-OHdG were measured in ocular tissue. The mRNA expression of NF-κB and Caspase-3 was also evaluated. Also, ocular sections were evaluated histopathologically. Bromelain demonstrated a dose-dependent protective effect in cisplatin-induced toxicity by regulating oxidative stress, inflammation, and tissue damage. Our results suggested that bromelain may be a potential adjuvant that can protect the eye from cisplatin-induced toxicity. © 2021 Informa UK Limited, trading as Taylor & Francis Group.Taylor and Francis Ltd.2023Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12059https://doi.org/10.1080/01480545.2021.20113080148-0545enDrug and Chemical Toxicologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12059